8
views
0
recommends
+1 Recommend
1 collections
    0
    shares

      Call for Papers: Sex and Gender in Neurodegenerative Diseases

      Submit here before September 30, 2024

      About Neurodegenerative Diseases: 3.0 Impact Factor I 4.3 CiteScore I 0.695 Scimago Journal & Country Rank (SJR)

      • Record: found
      • Abstract: found
      • Article: found

      Epidemiology of Myasthenia Gravis in Slovakia in the Years 1977–2015

      research-article

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Purpose: The objective of the study was to evaluate changes of epidemiological parameters in patients with myasthenia gravis (MG) in Slovakia during the period 1977–2015. Methods: Data from medical records of MG patients registered in Slovakia were analyzed. Epidemiological rates (incidence, prevalence, mortality) were assessed for several periods to identify changes and drifts over the period of study. Results: Out of 2,074 patients, 892 were males (43.0%) and 1,193 were females (57.0%). The thymoma associated MG (TAMG) was diagnosed in 123 patients (5.9%). The mean age at onset shifted from 35.8 years in 1977–1989 to 60.0 years in ­2010–2015. The crude incidence increased from 0.36/100,000 in 1977–1989 to 1.74/100,000 in 2010–2015. The average annual incidence of TAMG was 0.05/100,000. Maximum increase of MG incidence was registered among the elderly (≥50 years), particularly in the group of patients in the age range 70–79 years (0.34/100,000 in 1977–1989→7.10/100,000 in 2010–2015) and 80–89 years (0.00/100,000 in 1977–1989→5.31/100,000 in 2010–2015). The crude MG prevalence on December 31, 2015 was 24.75/100,000. The average MG mortality was 0.27/100,000. Conclusion: The age at onset and incidence increased significantly over the study period due to marked increase of MG incidence in elderly, particularly over 70 years. Possible reasons for this trend are discussed.

          Related collections

          Author and article information

          Journal
          NED
          Neuroepidemiology
          10.1159/issn.0251-5350
          Neuroepidemiology
          S. Karger AG
          0251-5350
          1423-0208
          2018
          May 2018
          20 March 2018
          : 50
          : 3-4
          : 153-159
          Affiliations
          [_a] aCentre for Neuromuscular Diseases, Department of Neurology, University Hospital Bratislava, Ruzinov, Slovakia
          [_b] bInstitute of Epidemiology, Medical Faculty, Comenius University, Bratislava, Slovakia
          Author notes
          *Ivan Martinka, MD, Centre for Neuromuscular Diseases, Department of Neurology, University Hospital Bratislava, Ruzinovska 6, SK–826 06 Ruzinov (Slovakia), E-Mail ivan.martinka@gmail.com
          Article
          487886 Neuroepidemiology 2018;50:153–159
          10.1159/000487886
          29558746
          af4043c0-396f-4b56-ae3a-ebae07a6ad93
          © 2018 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          History
          : 29 November 2017
          : 20 February 2018
          Page count
          Figures: 2, Tables: 5, Pages: 7
          Categories
          Original Paper

          Geriatric medicine,Neurology,Cardiovascular Medicine,Neurosciences,Clinical Psychology & Psychiatry,Public health
          Myasthenia gravis,Prevalence,Incidence,Mortality,Age at onset

          Comments

          Comment on this article